Munir Sidani

Munir Sidani

Auto-generated profile, based on publicly available information

Munir Sidani

§American University of Beirut Medical Center, Department of Internal Medicine, Beirut, Lebanon

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2025 in JBJS Reviews
Verified
Journal Article
Closed access
ARAkram Al Ramlawi
Akram Al Ramlawi
SCStephen W. Chenard
Stephen W. Chenard
MSMunir Sidani
Munir Sidani
JHJohn E. Herzenberg
John E. Herzenberg
JSJonathan G. Schoenecker
Jonathan G. Schoenecker
PMPhilip McClure
Philip McClure
» NF1 Link and Pathophysiology: Congenital pseudarthrosis of the tibia (CPT) is strongly associated with neurofibromatosis type 1 (NF1), where loss of normal NF1 gene function impairs bone formation and promotes fibrous hamartoma, resulting in recurrent tibial nonunion. » Classifications and Diagnostics: Multiple radiographic classifications (Andersen, Crawford, Boyd, Paley, etc.) guide clinical decision making, while newer imaging (magnetic resonance imaging, quantitative ultrasound) refines diagnosis and helps tailor interventions. » Treatment Modalities: Strategies range from nonoperative bracing (prefracture) to surgical approaches such as intramedullary rods (standard or telescopic), free vascularized fibular grafts, ring fixators (Ilizarov), and “cross-union” procedures—often combined with pharmacologic agents such as bone morphogenetic proteins (BMPs) or bisphosphonates. » Mixed Results With Pharmacologics: While rhBMP and bisphosphonates address bone catabolism and anabolism, neither agent alone has consistently succeeded in NF1-related CPT; combination regimens may offer better outcomes but require more robust research. » Future Directions: Ongoing studies explore early surgery (vs. waiting until age 2-3) and guided growth to address tibial bowing, molecular therapies (e.g., MAPK kinase and Src homology 2 containing protein tyrosine phosphatase 2 inhibitors), and refined fixation techniques. The management of CPT continues to evolve as genetic and cellular mechanisms become clearer.

13 May 2026 in Western Journal of Emergency Medicine
Verified
Journal Article
Open access
KHKegham Hawatian
Kegham Hawatian
JEJoshua Emakhu
Joshua Emakhu
TMThayer Morton
Thayer Morton
AHArqam Husain
Arqam Husain
HNHashem Nassereddine
Hashem Nassereddine
JMJoseph B Miller
Joseph B Miller
Introduction: Hypertension is a recognized risk factor for acute coronary syndrome and major adverse cardiovascular events, yet its influence on high sensitivity cardiac troponin (hscTn) concentrations and on the prognostic value of intermediate hscTnI results remains uncertain. We assessed whether blood pressure category confounds the relationship between intermediate hscTnI values (4-18 nanograms per liter [ng/L]) and 30-day major adverse cardiovascular events. Methods: We performed a secondary analysis of the Rapid Acute Coronary Syndrome Evaluation-Implementation Trial (steppedwedge randomized trial across nine Michigan emergency departments [ED] (July 2020–April 2021). From 32,609 patients in the primary trial, we analyzed only those with available hs-cTnI values reported to be in the intermediate range (4-18 ng/L). The first recorded ED blood pressure-determined category: normotensive (< 140/< 90 millimeters of mercury [mm Hg] moderate [140-179/90-109 mm Hg]; or severe [≥ 180/≥ 110 mm Hg]. Generalized linear models and penalized logistic regression examined associations with hscTnI and 30-day major adverse cardiovascular events (allcause death, myocardial infarction, or urgent revascularization), respectively, adjusting for confounders. Results: Analysis included 23,803 patients. Mean age was 57.5 ± 17.9 years; 57.5% were women and 32.7% Black. Blood pressure categories were normotensive 40.9%, moderate 46.5%, and severe 12.6%. After adjustment, severe blood pressure was associated with a 16% higher mean hscTnI (calculated as %change= 10β – 1; β = 0.064, 95%, CI 0.047-0.082). Major adverse cardiovascular events at 30-days occurred in 148 patients (0.6%), 47 of them normotensive (0.5%), 77 with moderate hypertension (0.7%), and 24 with severe hypertension (0.8%). Compared with normotension, moderate blood pressure independently increased 30-day major adverse cardiovascular events risk (adjusted odds ratio [AOR] 1.47, 95% CI, 1.02-2.13; absolute risk difference +0.25%, 95% CI, 0.01-0.49), whereas severe blood pressure showed no clear association (AOR 1.32, 95% CI, 0.80-2.18; absolute risk difference +0.17%, 95 % CI, −0.09 to 0.43). Estimates were similar in sensitivity analyses limited to patients without coronary artery disease. Conclusion: Among ED patients with intermediate hscTnI, blood pressure ≥ 140/90 mm Hg confers modestly higher short term risk of major adverse cardiovascular events, but incremental severity beyond this threshold does not add prognostic value. Elevated hscTnI in the context of severely elevated blood pressure likely reflects myocardial stress rather than additional ischemic risk. Clinicians should interpret intermediate troponin results in hypertensive patients cautiously, integrating clinical presentation and established risk factors.